Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss

Journal of Obstetrics and Gynaecology Research

Volumn 30, Issue 4, 2004, Pages 326-332

  Sugi, Toshitaka ^a   Matsubayashi, Hidehiko ^a   Inomo, Akifumi ^a   Dan, Lu ^a   Makino, Tsunehisa ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticardiolipin antibodies; Antiphosphatidylethanolamine antibodies; Antiphospholipid syndrome; Kininogen; Recurrent pregnancy loss

Indexed keywords

ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHATIDYLETHANOLAMINE ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY DISORDER; PREVALENCE; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ABORTION, HABITUAL; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; CARDIOLIPINS; FEMALE; GESTATIONAL AGE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATIDYLETHANOLAMINES; PREGNANCY;

EID: 4243094039     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2004.00206.x     Document Type: Article

References (34)

1. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
2. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
3. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulant and other 'antiphospholipid' autoantibodies. Blood 1994; 84: 2854-2867.
4. Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood 1995; 86: 3083-3089.
5. Sugi T, McIntyre JA. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001; 17: 207-214.
6. Hossain AM, Whitman GF, Khan I. Kininogen present in rat reproductive tissues is apparently synthesized by the liver, not by the reproductive system. Am J Obstet Gynecol 1995; 173: 830-834.
7. Hermann A, Buchinger P, Somlev B, Rehbock J. High and low molecular weight kininogen and plasma prekallikrein/plasma kallikrein in villous capillaries of human term placenta. Placenta 1996; 17: 223-230.
8. Brann DW, Greenbaum L, Mahesh VB, Gao X. Changes in kininogens and kallikrein in the plasma, brain, and uterus during pregnancy in the rat. Endocrinology 1995; 136: 46-51.
9. Adam A, Damas J, Galay G, Bourdon V. Quantification of rat T-kininogen using immunological methods. Biochem Pharmacol 1989; 38: 1569-1575.
10. Staub HL, Harris EN, Khamashta MH, Savidge G, Chahade WH, Hughes GR. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis 1989; 48: 166-169.
11. Karmochkine M, Cacoub P, Piette JC, Godear P, Boffa MC. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol 1992; 10: 603-605.
12. Karmochkine M, Berard M, Piette JC et al. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus 1993; 2: 157-160.
13. Boffa MC, Berard M, Sugi T, McIntyre JA. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity. J Rheumatol 1996; 23: 1375-1379.
14. Berard M, Chantome R, Marcelli A, Boffa MC. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996; 23: 1369-1374.
15. Balada E, Ordi-Ros J, Paredes F, Villarreal J, Mauri M, Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol 2001; 30: 235-241.
16. Sanmarco M, Alessi MC, Harle JR et al. Antibodies to phosphatidylethanolamine as the only antiphopsholipid antibodies found in patients with unexplained thrombosis. Thromb Haemost 2001; 85: 800-805.
17. Sugi T, Katsunuma J, Izumi S, McIntyre JA, Makino T. Prevalence and heterogeneity of antiphosphatidylethanolaime antibodies in patients with recurrent early pregnancy losses. Fertil Steril 1999; 71: 1060-1065.
18. Gris JC, Quere I, Sanmarco M et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. Thromb Haemost 2000; 84: 228-236.
19. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313: 1322-1326.
20. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Adv Rheumatol 1997; 81: 151-177.
21. Katano K, Aoki K, Sasa H, Ogasawara M, Matsuura E, Yagami Y. β2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509-512.
22. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104.
23. Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy J, Gruel Y. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88: 900-906.
24. Weerasinghe KM, Gadsby JE. The presence of glandular kallikrein in rabbit fetal placental conditioned medium. Endocrinology 1992; 131: 1777-1781.
25. Mutoh S, Kobayashi M, Hirata J et al. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium. Agents Actions 1992; 38(Part 2): 320-329.
26. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522.
27. Colman RW, Schmaier AH. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, anti-adhesive, and proinflammatory attributes. Blood 1997; 90: 3819-3843.
28. Meloni FJ, Schmaier AH. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 1991; 266: 6786-6794.
29. Schmaier AH, Smith PM, Purdon AD, White JG, Colman RW. High molecular weight kininogen. Localization in the unstimulated and activated platelet and activation by a platelet calpain(s). Blood 1986; 67: 119-130.
30. Gustafson EJ, Schutsky D, Knight LC, Schmaier AH. High molecular weight kininogen binds to unstimulated platelets. J Clin Invest 1986; 78: 310-318.
31. Jiang YP, Muller-Esterl W, Schmaier AH. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J Biol Chem 1992; 267: 3712-3717.
32. Kunapuli SP, Bradford HN, Jameson BA et al. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 domain 3 in the heavy chain of high molecular weight kininogen. J Biol Chem 1996; 271: 11228.
33. Sugi T, McIntyre JA. Autoantibodies to kininogen phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation. Thromb Res 1996; 84: 97-109.
34. Katsunuma J, Sugi T, Inomo A, Matsubayashi H, Izumi SI, Makino T. Kininogen domain 3 contains regions recognized by antiphosphatidylethanolamine antibodies. J Thromb Haemost 2003; 1: 132-138.